Brought to you by MedPage Today.
1. Off-Label Chemo Common for Mets. Off-label prescribing of chemotherapy agents is common in the metastatic setting and a substantial proportion of it goes beyond National Comprehensive Cancer Network (NCCN)-accepted practice.
2. FDA Panel Starts to Tackle Avandia Safety. A controversial study of the cardiovascular safety of one-time diabetes blockbuster rosiglitazone (Avandia) has proven difficult for FDA and independent reviewers to reanalyze.
3. Just 1 Doc in 10 Meets Meaningful Use Criteria. More physicians are using electronic health records (EHRs), but a significantly smaller proportion of eligible physicians say they have met the first stage of meaningful use criteria.